论文部分内容阅读
目的:探讨晚期及复发性胃癌行替吉奥联合奥沙利铂及多西他赛治疗的疗效及安全性。方法:回顾性分析我院诊治的晚期及复发性胃癌患者65例,按照不同的治疗方案分为两组,对照组32例行替吉奥联合多西他赛治疗,研究组33例行替吉奥联合奥沙利铂治疗,比较两组的近期疗效及不良反应情况。结果:研究组治疗有效率54.54%略高于对照组53.12%,差异无统计学意义(P>0.05);研究组不良反应发生率比对照组低,具统计学意义(P<0.05)。结论:奥沙利铂与多西他赛联合替吉奥应用于晚期及复发性胃癌患者的疗效相当,但联合奥沙利铂不良反应更轻。
Objective: To investigate the efficacy and safety of tirgilib combined with oxaliplatin and docetaxel in the treatment of advanced and recurrent gastric cancer. Methods: A retrospective analysis of 65 cases of advanced and recurrent gastric cancer diagnosed and treated in our hospital were divided into two groups according to different treatment regimens. The control group of 32 patients treated with combined treatment of docetaxel and docetaxel, 33 cases of study group Austrian joint oxaliplatin treatment, the two groups compared the short-term efficacy and adverse reactions. Results: The effective rate of study group was 54.54%, which was slightly higher than that of control group (53.12%) (P> 0.05). The adverse reaction rate of study group was lower than that of control group (P <0.05). Conclusion: Oxaliplatin and docetaxel are effective in treating patients with advanced and recurrent gastric cancer, but the side effects of combined oxaliplatin are lighter.